Health
Pfizer’s COVID vaccine shows ‘robust’ results in early trial – Medical Xpress
(HealthDay)—A vaccine based on cutting-edge RNA gene technology showed promising potency against the new coronavirus in an early trial, scientists report.
by E.j. Mundell, Healthday Reporter (HealthDay)A vaccine based on cutting-edge RNA gene technology showed promising potency against the new coronavirus in an early trial, scientists report.
The vaccine candidatefor now just called BNT162b1″elicited a robust immune response in participants, which increased with dose level and with a second dose,” according to a news release from the journal Nature, which published the trial data on Aug. 12.
The early phase 1/2 trial was led by Dr. Judith Absal…
-
General22 hours agoCan recognising the state of Palestine achieve a two-state solution as Israel continues bombing Gaza?
-
Noosa News16 hours agoCelebrate 200 years of steam trains with a ride on the Rattler
-
Business15 hours agoUp 64% in a month! This unique ASX uranium stock is leading the charge amidst sector-wide rally
-
Noosa News16 hours agoQueensland Health staff to “hot desk” for $50m budget saving